Aziyo Biologics, Inc.

55 articles with Aziyo Biologics, Inc.

• Aziyo Biologics Appoints Peter G. Edwards as General Counsel

  8/31/2021

  Aziyo Biologics, Inc., a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, announced the appointment of Peter G. Edwards as General Counsel.

• Aziyo Biologics Reports Second Quarter 2021 Financial Results

  8/9/2021

  Aziyo Biologics, Inc., a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, reported financial results for the three and six months ended June 30, 2021.

• Aziyo Biologics to Report Second Quarter 2021 Financial Results on Monday, August 9, 2021

  7/26/2021

  Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced that it plans to release its second quarter earnings results after market close on Monday, August 9, 2021.

• 

  Excessive Impurities Cause Recall of Pfizer's Anti-Smoking Drug

  7/20/2021

  Pfizer has voluntarily recalled two lots of Chantix 0.5 mg tablets, two lots of Chantix 1 mg tablets, and eight lots of a Chantix kit consisting of 0.5mg/1 mg tablets.

• Aziyo Biologics Comments on June 2nd Voluntary Recall of One Lot of its FiberCel Fiber Viable Bone Matrix

  6/7/2021

  Aziyo Biologics, Inc. (Nasdaq: AZYO) on June 2, 2021 issued a voluntary recall pertaining to a single donor lot of its FiberCel Fiber Viable Bone Matrix, a bone repair product made from human tissue that is used in various orthopedic and spinal procedures.

• Aziyo Biologics Reports First Quarter 2021 Financial Results and Increases 2021 Revenue Guidance

  5/4/2021

  Aziyo Biologics, Inc., a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, reported financial results for the three months ended March 31, 2021.

• Aziyo Biologics Announces Initiation of De Novo CanGaroo Clinical Study

  4/28/2021

  Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, announced today the initiation of a multi-center observational study to provide insight into the clinical profiles, procedural details and post-implant outcomes in patients receiving Aziyo’s CanGaroo® Envelope or no envelope during initial

• Aziyo Biologics to Participate in the Truist Securities Life Sciences Summit

  4/26/2021

  Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced the Company will participate in the upcoming Truist Securities Life Sciences Summit. Date: Wednesday, May 5, 2021

• Aziyo Biologics to Report First Quarter 2021 Financial Results on Tuesday, May 4, 2021

  4/20/2021

  Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced that it plans to release its first quarter earnings results after market close on Tuesday, May 4, 2021.

• Aziyo Biologics Reports Fourth Quarter and Full Year 2020 Financial Results

  3/1/2021

  Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today reported financial results for the fourth quarter and full year ended December 31, 2020.

• Aziyo Biologics to Participate in the Cowen 41st Annual Health Care Conference

  2/18/2021

  Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced the Company will participate in the upcoming Cowen 41st Annual Health Care Conference.

• Aziyo Biologics Announces First Patient Enrolled in HEAL Study

  2/17/2021

  Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, announced today the first patient enrolled in the HEAL Study,

• Aziyo Biologics to Report Fourth Quarter and Full Year 2020 Financial Results on Monday, March 1, 2021

  2/15/2021

  Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced that it plans to release its fourth quarter and full year earnings results after market close on Monday, March 1, 2021.

• Aziyo Biologics Announces Product Design Completion for its Next Generation CanGaroo® Envelope for Implantable Electronic Devices

  2/11/2021

  Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, announced today product design completion for CanGaroo® with antibiotics, the next generation of the Company’s CanGaroo Envelope.

• Aziyo Biologics Announces Updated CanGaroo® Envelope Label in European Markets to Allow for Hydration in an Antibiotic Solution

  1/28/2021

  Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, announced that it has received CE Mark approval for updated labeling of the Company’s biological CanGaroo® Envelope to allow for the addition of the antibiotic gentamicin. While the indications of the CanGaroo Envelope remain unchanged

• Aziyo Biologics Reports Third Quarter 2020 Financial Results

  11/19/2020

  Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today reported financial results for the three and nine months ended September 30, 2020.

• Aziyo Biologics to Participate in the Piper 32nd Annual Virtual Healthcare Conference

  11/17/2020

  Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced the Company will participate in the upcoming Piper Virtual Healthcare Conference

• Aziyo Biologics Awarded Breakthrough Technology Contract with Premier Inc.

  11/12/2020

  Aziyo Biologics, Inc., a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, has been awarded a group purchasing agreement with Premier Inc., for Premier’s Technology Breakthroughs Program.

• Aziyo Biologics to Report Third Quarter 2020 Financial Results on Thursday, November 19, 2020

  11/5/2020

  Aziyo Biologics, Inc., a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, announced that it plans to release its third quarter earnings results after market close on Thursday, November 19, 2020.

• Aziyo Biologics Announces Pricing of Initial Public Offering

  10/7/2020

  Aziyo Biologics, Inc. (Nasdaq: AZYO) today announced the pricing of its initial public offering of 2,941,176 shares of common stock, consisting of 2,205,882 shares of Class A common stock and 735,294 shares of Class B common stock,